PRAKASH MASAND to Middle Aged
This is a "connection" page, showing publications PRAKASH MASAND has written about Middle Aged.
Connection Strength
0.314
-
Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder and Anxious Distress: Post Hoc Analysis of a Phase 3, Randomized, Double-Blind Trial. J Clin Psychiatry. 2026 Sep 14; 87(3).
Score: 0.059
-
Health care resource utilization and costs associated with switching versus augmenting antidepressant monotherapy in second-line treatment of major depressive disorder. J Affect Disord. 2025 Dec 15; 391:119787.
Score: 0.054
-
Quetiapine augmentation for depression: dosing pattern in routine practice. Int Clin Psychopharmacol. 2015 Jan; 30(1):54-8.
Score: 0.026
-
A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome. Psychosomatics. 2009 Jan-Feb; 50(1):78-86.
Score: 0.017
-
The effect of adjunctive cariprazine on symptoms of anhedonia in patients with major depressive disorder. J Affect Disord. 2025 Sep 15; 385:119366.
Score: 0.013
-
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature. 2025 01; 637(8047):940-946.
Score: 0.013
-
Biomarkers for liver disease in urea cycle disorders. Mol Genet Metab. 2021 06; 133(2):148-156.
Score: 0.010
-
Reduced plasma Fetuin-A is a promising biomarker of depression in the elderly. Eur Arch Psychiatry Clin Neurosci. 2020 Oct; 270(7):901-910.
Score: 0.009
-
Cariprazine for the treatment of bipolar mania with mixed features: A post hoc pooled analysis of 3 trials. J Affect Disord. 2019 10 01; 257:600-606.
Score: 0.009
-
Reduced CXCL1/GRO chemokine plasma levels are a possible biomarker of elderly depression. J Affect Disord. 2019 Apr 15; 249:410-417.
Score: 0.009
-
Neuroplasticity, Neurotransmission and Brain-Related Genes in Major Depression and Bipolar Disorder: Focus on Treatment Outcomes in an Asiatic Sample. Adv Ther. 2018 10; 35(10):1656-1670.
Score: 0.008
-
A prospective multicenter study of competency evaluations by psychiatric consultation services. Psychosomatics. 1998 Jan-Feb; 39(1):55-60.
Score: 0.008
-
Genetic Variants Within Molecular Targets of Antipsychotic Treatment: Effects on Treatment Response, Schizophrenia Risk, and Psychopathological Features. J Mol Neurosci. 2018 Jan; 64(1):62-74.
Score: 0.008
-
Genetic Variants Within Key Nodes of the Cascade of Antipsychotic Mechanisms: Effects on Antipsychotic Response and Schizophrenia Psychopathology in a Naturalistic Treatment Setting in Two Independent Korean and Italian Samples. Adv Ther. 2017 06; 34(6):1482-1497.
Score: 0.008
-
The Impact of a Single Nucleotide Polymorphism in SIGMAR1 on Depressive Symptoms in Major Depressive Disorder and Bipolar Disorder. Adv Ther. 2017 03; 34(3):713-724.
Score: 0.008
-
The influence of AHI1 variants on the diagnosis and treatment outcome in schizophrenia. Int J Mol Sci. 2015 Jan 22; 16(2):2517-29.
Score: 0.007
-
A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state. PLoS One. 2012; 7(4):e34757.
Score: 0.005
-
Psychometric properties of the Patient Health Questionnaire-15 (PHQ-15) for measuring the somatic symptoms of psychiatric outpatients. Psychosomatics. 2009 Nov-Dec; 50(6):580-5.
Score: 0.005
-
History of depressive and/or anxiety disorders as a predictor of treatment response: a post hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release in patients with fibromyalgia. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Aug 31; 33(6):996-1002.
Score: 0.004
-
Left ventricular myocardial bands: MDCT and MR appearance. J Thorac Imaging. 2009 May; 24(2):119-24.
Score: 0.004
-
Methylphenidate extended release (OROS MPH) for the treatment of antidepressant-related sexual dysfunction in patients with treatment-resistant depression: results from a 4-week, double-blind, placebo-controlled trial. Clin Neuropharmacol. 2009 Mar-Apr; 32(2):85-8.
Score: 0.004
-
Childhood abuse and treatment response in patients with irritable bowel syndrome: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release. J Clin Pharm Ther. 2009 Feb; 34(1):79-88.
Score: 0.004
-
History of early abuse as a predictor of treatment response in patients with fibromyalgia: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release. World J Biol Psychiatry. 2009; 10(4 Pt 2):435-41.
Score: 0.004
-
Polypharmacy in pregnant women with major psychiatric illness: a pilot study. J Psychiatr Pract. 2007 Nov; 13(6):385-92.
Score: 0.004
-
A randomized, controlled, trial of controlled release paroxetine in fibromyalgia. Am J Med. 2007 May; 120(5):448-54.
Score: 0.004
-
A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. J Clin Psychopharmacol. 2006 Dec; 26(6):653-6.
Score: 0.004
-
Clinical variables associated with early administration of antipsychotics in bipolar mania. Prog Neuropsychopharmacol Biol Psychiatry. 2006 Jan; 30(1):151-4.
Score: 0.003